New hope for recurrent brain cancer? early trial of CUE-102 begins

NCT ID NCT06917885

Recruiting now Disease control Sponsor: David Reardon, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental drug called CUE-102 in 18 adults with recurrent glioblastoma, a type of brain cancer that has come back. The drug is a fusion protein designed to help the immune system attack cancer cells. The main goal is to find a safe dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CUE-102 (a fusion protein that targets cancer cells and boosts immune response)
What this could lead to: If it works, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few options.
What could go wrong: This is a very early, small Phase 1 trial with only 18 people. The main goal is safety, not effectiveness. It may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOMA, MALIGNANT RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Brigham and Women's Hospital
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.